Pharvaris N.V. (PHVS) stock
PHVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$33.83−0.35 (-1.02%)
Close on Nov 12, 2026Market cap $2.21BP/E –Yield –
Pharvaris EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -2.97 EUR. The highest annual figure on record is -0.89 EUR in fiscal 2018.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -2.97 EUR | – |
| FY2024 | Dec 31, 2024 | -2.48 EUR | – |
| FY2023 | Dec 31, 2023 | -2.63 EUR | – |
| FY2022 | Dec 31, 2022 | -2.27 EUR | – |
| FY2021 | Dec 31, 2021 | -1.40 EUR | – |
| FY2020 | Dec 31, 2020 | -5.36 EUR | – |
| FY2019 | Dec 31, 2019 | -1.66 EUR | – |
| FY2018 | Dec 31, 2018 | -0.89 EUR | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -0.70 EUR | – |
| Q2 FY2025 | Jun 30, 2025 | -0.83 EUR | – |
| Q2 FY2024 | Jun 30, 2024 | -0.55 EUR | – |
| Q2 FY2023 | Jun 30, 2023 | -0.63 EUR | – |
| Q2 FY2022 | Jun 30, 2022 | -0.38 EUR | – |
| Q2 FY2021 | Jun 30, 2021 | -0.46 EUR | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?